Venetoclax/Venetoclax (Vekela) contraindications and instructions for those who should take it with caution

Venetoclax is a selective BCL-2 inhibitor, mainly used to treat hematological tumors such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Because its mechanism of action involves the rapid induction of apoptosis in cancer cells, it may induce tumor lysis syndrome (TLS) in some patients. Therefore, it is important to identify drug contraindications, which mainly include patients who are allergic to venetoclax or any component of the preparation, as well as patients with severe hepatic impairment or uncontrollable renal dysfunction.

Veneclar may causeTLS in patients with high tumor burden, manifested by hyperuricemia, elevated serum potassium, elevated serum phosphorus and abnormal renal function. For patients with extremely high white blood cell counts or large tumors, gradual dose escalation under physician guidance is required, combined with hydration, pharmacological prophylaxis (such as allopurinol), and close monitoring of blood markers. If the patient has heart disease or electrolyte imbalances, these should be corrected before taking the medication to reduce risk.

Patients with hepatic and renal insufficiency should be cautious when using venetoclax, as drug metabolism and excretion may be affected, increasing the risk of adverse reactions. In addition, venetoclax has significant drug interactions with strong CYP3A inhibitors or inducers. Concomitant use may result in excessive blood concentration or reduced efficacy. Therefore, the dosage must be adjusted under the guidance of a doctor and relevant indicators must be monitored to ensure safety.

Venetoclax should also be used with caution in elderly patients, those who are frail or at risk for serious infections. During use, blood routine, electrolytes, liver and kidney functions need to be monitored regularly, and the dose should be adjusted or the dose escalation cycle should be extended according to the patient's specific conditions. At the same time, patients and their families should be educated to pay attention to potential adverse reactions, such as fever, fatigue, bleeding or palpitations, and seek medical treatment in a timely manner. Through standardized management and monitoring, medication risks can be effectively reduced and treatment safety improved.

Reference materials:https://www.drugs.com/